tiprankstipranks
Trending News
More News >
Exact Sciences Corp (EXAS)
:EXAS
US Market

Exact Sciences (EXAS) Stock Forecast & Price Target

Compare
3,287 Followers
See the Price Targets and Ratings of:

EXAS Analyst Ratings

Strong Buy
18Ratings
Strong Buy
17 Buy
1 Hold
0 Sell
Based on 18 analysts giving stock ratings to
Exact
Sciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

EXAS Stock 12 Month Forecast

Average Price Target

$69.63
▲(34.39%Upside)
Based on 18 Wall Street analysts offering 12 month price targets for Exact Sciences in the last 3 months. The average price target is $69.63 with a high forecast of $90.00 and a low forecast of $54.00. The average price target represents a 34.39% change from the last price of $51.81.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"41":"$41","66":"$66","91":"$91","53.5":"$53.5","78.5":"$78.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$90.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":69.63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$69.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$54.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[41,53.5,66,78.5,91],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.13,58.73538461538462,61.34076923076923,63.94615384615385,66.55153846153846,69.15692307692308,71.7623076923077,74.36769230769231,76.97307692307692,79.57846153846154,82.18384615384616,84.78923076923077,87.39461538461538,{"y":90,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.13,57.16846153846154,58.206923076923076,59.245384615384616,60.283846153846156,61.32230769230769,62.36076923076923,63.39923076923077,64.4376923076923,65.47615384615385,66.51461538461538,67.55307692307692,68.59153846153846,{"y":69.63,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.13,55.96615384615385,55.80230769230769,55.63846153846154,55.47461538461538,55.31076923076923,55.14692307692308,54.98307692307692,54.81923076923077,54.65538461538462,54.49153846153846,54.32769230769231,54.16384615384615,{"y":54,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":45.45,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.43,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.91,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.69,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.04,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.8,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.69,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.19,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.05,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.41,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.45,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.13,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$90.00Average Price Target$69.63Lowest Price Target$54.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on EXAS
TipRanks AITipRanks
Not Ranked
TipRanks
$56
Hold
8.09%
Upside
Reiterated
06/13/25
Exact Sciences' overall stock score is primarily driven by strong earnings call results, reflecting revenue growth and improved profitability. However, significant profitability challenges and valuation concerns due to a negative P/E ratio weigh on the score. Technical indicators provide moderate support, suggesting a potential for price increases, while financial performance indicates the need for improved profitability and cash flow conversion.
Bank of America Securities Analyst forecast on EXAS
Michael RyskinBank of America Securities
Bank of America Securities
$70
Buy
35.11%
Upside
Reiterated
06/25/25
Exact Sciences (EXAS) Receives a Buy from Bank of America Securities
TD Cowen
$75
Buy
44.76%
Upside
Reiterated
06/24/25
Exact Sciences (EXAS) Receives a Buy from TD Cowen
Barclays Analyst forecast on EXAS
Luke SergottBarclays
Barclays
$75$65
Buy
25.46%
Upside
Reiterated
06/24/25
Exact Sciences price target lowered to $65 from $75 at BarclaysExact Sciences price target lowered to $65 from $75 at Barclays
RBC Capital Analyst forecast on EXAS
Conor McNamaraRBC Capital
RBC Capital
$54
Hold
4.23%
Upside
Reiterated
06/05/25
Wells Fargo
$68
Buy
31.25%
Upside
Reiterated
06/02/25
Analysts Offer Insights on Healthcare Companies: Exact Sciences (NASDAQ: EXAS) and Arcus Biosciences (NYSE: RCUS)
Leerink Partners Analyst forecast on EXAS
Puneet SoudaLeerink Partners
Leerink Partners
$90
Buy
73.71%
Upside
Reiterated
06/02/25
Exact Sciences' Growth Potential Boosted by NCCN Guideline Inclusion and Expanding Market Reach
Piper Sandler Analyst forecast on EXAS
David WestenbergPiper Sandler
Piper Sandler
$70
Buy
35.11%
Upside
Reiterated
05/15/25
Piper Sandler Sticks to Their Buy Rating for Exact Sciences (EXAS)
Scotiabank Analyst forecast on EXAS
Sung Ji NamScotiabank
Scotiabank
$73
Buy
40.90%
Upside
Reiterated
05/06/25
Exact Sciences (EXAS) Gets a Buy from Scotiabank
Robert W. Baird
$69$72
Buy
38.97%
Upside
Reiterated
05/02/25
Exact Sciences price target raised to $72 from $69 at BairdExact Sciences price target raised to $72 from $69 at Baird
Jefferies
$80
Buy
54.41%
Upside
Reiterated
05/02/25
Exact Sciences: Strong Q1 Performance and Promising Outlook Justify Buy Rating
William Blair Analyst forecast on EXAS
Andrew BrackmannWilliam Blair
William Blair
Buy
Reiterated
05/02/25
Exact Sciences: Strong Q1 Performance and Promising Prospects Justify Buy Rating
Stifel Nicolaus Analyst forecast on EXAS
Daniel AriasStifel Nicolaus
Stifel Nicolaus
$67
Buy
29.32%
Upside
Reiterated
05/02/25
Exact Sciences (EXAS) Gets a Buy from Stifel Nicolaus
Benchmark Co. Analyst forecast on EXAS
Bruce JacksonBenchmark Co.
Benchmark Co.
$65
Buy
25.46%
Upside
Reiterated
05/02/25
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND) and Exact Sciences (NASDAQ: EXAS)
Canaccord Genuity Analyst forecast on EXAS
Kyle Mikson CFACanaccord Genuity
Canaccord Genuity
$75
Buy
44.76%
Upside
Reiterated
05/01/25
Analysts Offer Insights on Healthcare Companies: Dexcom (NASDAQ: DXCM) and Exact Sciences (NASDAQ: EXAS)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on EXAS
TipRanks AITipRanks
Not Ranked
TipRanks
$56
Hold
8.09%
Upside
Reiterated
06/13/25
Exact Sciences' overall stock score is primarily driven by strong earnings call results, reflecting revenue growth and improved profitability. However, significant profitability challenges and valuation concerns due to a negative P/E ratio weigh on the score. Technical indicators provide moderate support, suggesting a potential for price increases, while financial performance indicates the need for improved profitability and cash flow conversion.
Bank of America Securities Analyst forecast on EXAS
Michael RyskinBank of America Securities
Bank of America Securities
$70
Buy
35.11%
Upside
Reiterated
06/25/25
Exact Sciences (EXAS) Receives a Buy from Bank of America Securities
TD Cowen
$75
Buy
44.76%
Upside
Reiterated
06/24/25
Exact Sciences (EXAS) Receives a Buy from TD Cowen
Barclays Analyst forecast on EXAS
Luke SergottBarclays
Barclays
$75$65
Buy
25.46%
Upside
Reiterated
06/24/25
Exact Sciences price target lowered to $65 from $75 at BarclaysExact Sciences price target lowered to $65 from $75 at Barclays
RBC Capital Analyst forecast on EXAS
Conor McNamaraRBC Capital
RBC Capital
$54
Hold
4.23%
Upside
Reiterated
06/05/25
Wells Fargo
$68
Buy
31.25%
Upside
Reiterated
06/02/25
Analysts Offer Insights on Healthcare Companies: Exact Sciences (NASDAQ: EXAS) and Arcus Biosciences (NYSE: RCUS)
Leerink Partners Analyst forecast on EXAS
Puneet SoudaLeerink Partners
Leerink Partners
$90
Buy
73.71%
Upside
Reiterated
06/02/25
Exact Sciences' Growth Potential Boosted by NCCN Guideline Inclusion and Expanding Market Reach
Piper Sandler Analyst forecast on EXAS
David WestenbergPiper Sandler
Piper Sandler
$70
Buy
35.11%
Upside
Reiterated
05/15/25
Piper Sandler Sticks to Their Buy Rating for Exact Sciences (EXAS)
Scotiabank Analyst forecast on EXAS
Sung Ji NamScotiabank
Scotiabank
$73
Buy
40.90%
Upside
Reiterated
05/06/25
Exact Sciences (EXAS) Gets a Buy from Scotiabank
Robert W. Baird
$69$72
Buy
38.97%
Upside
Reiterated
05/02/25
Exact Sciences price target raised to $72 from $69 at BairdExact Sciences price target raised to $72 from $69 at Baird
Jefferies
$80
Buy
54.41%
Upside
Reiterated
05/02/25
Exact Sciences: Strong Q1 Performance and Promising Outlook Justify Buy Rating
William Blair Analyst forecast on EXAS
Andrew BrackmannWilliam Blair
William Blair
Buy
Reiterated
05/02/25
Exact Sciences: Strong Q1 Performance and Promising Prospects Justify Buy Rating
Stifel Nicolaus Analyst forecast on EXAS
Daniel AriasStifel Nicolaus
Stifel Nicolaus
$67
Buy
29.32%
Upside
Reiterated
05/02/25
Exact Sciences (EXAS) Gets a Buy from Stifel Nicolaus
Benchmark Co. Analyst forecast on EXAS
Bruce JacksonBenchmark Co.
Benchmark Co.
$65
Buy
25.46%
Upside
Reiterated
05/02/25
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND) and Exact Sciences (NASDAQ: EXAS)
Canaccord Genuity Analyst forecast on EXAS
Kyle Mikson CFACanaccord Genuity
Canaccord Genuity
$75
Buy
44.76%
Upside
Reiterated
05/01/25
Analysts Offer Insights on Healthcare Companies: Dexcom (NASDAQ: DXCM) and Exact Sciences (NASDAQ: EXAS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Exact Sciences

1 Month
xxx
Success Rate
25/39 ratings generated profit
64%
Average Return
+7.36%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 64.10% of your transactions generating a profit, with an average return of +7.36% per trade.
3 Months
xxx
Success Rate
25/39 ratings generated profit
64%
Average Return
+19.61%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 64.10% of your transactions generating a profit, with an average return of +19.61% per trade.
1 Year
Doug SchenkelWolfe Research
Success Rate
15/21 ratings generated profit
71%
Average Return
+32.80%
reiterated a buy rating 9 months ago
Copying Doug Schenkel's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +32.80% per trade.
2 Years
xxx
Success Rate
25/39 ratings generated profit
64%
Average Return
+120.07%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 64.10% of your transactions generating a profit, with an average return of +120.07% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EXAS Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
4
6
9
8
7
Buy
24
25
19
23
22
Hold
0
1
3
4
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
28
32
31
35
33
In the current month, EXAS has received 29 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. EXAS average Analyst price target in the past 3 months is 69.63.
Each month's total comprises the sum of three months' worth of ratings.

EXAS Financial Forecast

EXAS Earnings Forecast

Next quarter’s earnings estimate for EXAS is -$0.13 with a range of -$0.62 to $0.09. The previous quarter’s EPS was -$0.54. EXAS beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 50.00% of the time in the same period. In the last calendar year EXAS has Outperformed its overall industry.
Next quarter’s earnings estimate for EXAS is -$0.13 with a range of -$0.62 to $0.09. The previous quarter’s EPS was -$0.54. EXAS beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 50.00% of the time in the same period. In the last calendar year EXAS has Outperformed its overall industry.

EXAS Sales Forecast

Next quarter’s sales forecast for EXAS is $773.46M with a range of $768.86M to $777.88M. The previous quarter’s sales results were $706.78M. EXAS beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 50.56% of the time in the same period. In the last calendar year EXAS has Outperformed its overall industry.
Next quarter’s sales forecast for EXAS is $773.46M with a range of $768.86M to $777.88M. The previous quarter’s sales results were $706.78M. EXAS beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 50.56% of the time in the same period. In the last calendar year EXAS has Outperformed its overall industry.

EXAS Stock Forecast FAQ

What is EXAS’s average 12-month price target, according to analysts?
Based on analyst ratings, Exact Sciences Corp’s 12-month average price target is 69.63.
    What is EXAS’s upside potential, based on the analysts’ average price target?
    Exact Sciences Corp has 34.39% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is EXAS a Buy, Sell or Hold?
          Exact Sciences Corp has a consensus rating of Strong Buy which is based on 17 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Exact Sciences Corp’s price target?
            The average price target for Exact Sciences Corp is 69.63. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $90.00 ,the lowest forecast is $54.00. The average price target represents 34.39% Increase from the current price of $51.81.
              What do analysts say about Exact Sciences Corp?
              Exact Sciences Corp’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.
                How can I buy shares of EXAS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis